Coral Laboratories Ltd

CORALAB

Watchlist

AI Mode

‌

Market Cap

₹ 163 Cr

P/E

9.24

‌

‌
‌

‌

‌
‌

Investment Checklist

How to read checklist?

Performance

STEADY PERFORMER

Valuation

UNDERVALUED

Growth

STABLE

Profitability

MODERATE MARGIN

Technicals

Bearish

Risk

LOW RISK

Investment Checklist

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

Price

PE Ratio

Price

‌

Overview

Detailed Summary

Coral Laboratories Limited (CLL) is a pharmaceutical company focused on manufacturing generic branded, nutraceuticals, OTC, and herbal medicines across India.

The company operates three production facilities located in Daman and Dehradun, enhancing its manufacturing capacity and scope.

Originally promoted by Navin B Doshi of the DWD group, Coral Labs raised Rs. 2.5 crores through a public issue to expand its manufacturing capabilities.

Coral Laboratories began commercial production at its ultra-modern unit in Daman in March 2004 and its plant in Dehradun in September 2006.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Formulations

Market Cap

163 Cr

Volatility

Low Risk

P/E Ratio

9.2

Industry P/E

43.8

PEG Ratio

0.2

P/B Ratio

0.8

52W High

859.00

52W Low

431.10

Sales CAGR

37.47%

15.00%

10.26%

10Y

4.32%

Profit CAGR

53.01%

38.74%

27.64%

10Y

7.69%

ROE

TTM

8.14%

8.70%

8.35%

10Y

9.43%

ROCE

TTM

10.97%

11.29%

10.74%

10Y

12.66%

Technicals

‌

Forecasts

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
BDH	414.75	228 Cr	23.35	3.28	1.14	13.80	18.80	10.96
PHARMAID	49.98	176 Cr	—	3.40	0.00	-31.40	-26.23	-15.87
CORALAB	452.00	163 Cr	9.24	0.77	0.00	8.14	10.97	7.45
PARNAXLAB	127.20	143 Cr	12.93	1.58	0.00	12.26	12.71	5.29
QUESTLAB	86.30	142 Cr	10.02	1.58	0.00	15.73	15.08	10.18
APPL	161.00	110 Cr	—	5.49	0.00	15.67	18.38	8.59
MERCURYLAB	836.80	100 Cr	20.40	1.80	0.42	8.81	11.49	6.63

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Standalone Quarterly Results (in ₹ Crores)

Total Figures

QoQ Changes

Total Figures

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	14	23	18	29	32	32	23	28	19	19
Expenses	12	17	16	23	21	26	17	25	17	14
Operating Profit	1.75	6.16	2.10	6.25	11	6.51	6.31	2.68	2.18	4.93
OPM %	12.92	26.61	11.62	21.63	33.92	20.20	27.45	9.53	11.58	25.91
Other Income	1.29	1.81	1.37	2.00	1.56	2.54	2.52	1.71	2.05	3.03
Interest	0.00	0.00	0.00	0.00	0.03	0.01	0.02	0.04	0.06	0.10
Depreciation	0.55	0.44	0.49	0.50	0.49	0.51	0.50	0.51	0.45	0.45
Profit Before Tax	2.49	7.52	2.98	7.74	12	8.53	8.31	3.85	3.72	7.42
Tax %	26.10	20.21	27.52	25.32	25.23	25.21	26.11	26.49	31.18	21.56
Net Profit	1.84	6.00	2.16	5.79	8.80	6.38	6.14	2.83	2.56	5.82
EPS in Rs	5.16	16.81	6.04	16.20	24.64	17.86	17.20	7.91	7.18	16.29

Standalone Profit Loss (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	95	92	91	71	97	76	78	84	115	102
Expenses	72	77	79	65	81	67	74	67	89	84
Operating Profit	23	15	12	5.29	16	8.21	3.81	16	26	18
OPM %	24.21	16.41	13.48	7.50	16.41	10.86	4.88	19.41	22.82	17.30
Other Income	3.04	4.47	5.16	5.89	3.79	5.77	6.93	6.47	8.34	8.82
Interest	0.03	0.03	0.02	0.06	0.04	0.14	0.34	0.00	0.10	0.13
Depreciation	1.56	1.56	1.90	2.01	1.98	1.99	2.18	1.98	2.01	1.97
Profit Before Tax	25	18	16	9.12	18	12	8.23	21	32	24
Tax %	33.66	31.05	34.11	21.79	23.04	23.70	21.65	23.84	25.61	26.63
Net Profit	16	12	10	7.13	14	9.05	6.45	16	24	18
EPS in Rs	45.61	34.84	28.61	19.96	37.95	25.32	18.04	44.21	67.61	48.58
Dividend Payout %	10.96	5.74	6.99	0.00	0.00	0.00	0.00	0.00	0.00	—

Standalone Balance Sheet (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	3.57	3.57	3.57	3.57	3.57	3.57	3.57	3.57	3.57	3.57
Reserves	67	106	113	110	112	133	152	151	174	198
Borrowings	0.37	2.17	1.74	1.44	5.91	6.25	6.04	0.00	0.00	3.56
Other Liabilities	19	20	22	21	23	25	28	20	28	25
Total Liabilities	89	131	140	136	144	168	190	174	206	229
Fixed Assets	18	18	22	22	22	20	23	24	23	22
CWIP	0.00	0.23	0.00	0.00	0.00	0.50	1.72	0.00	0.00	2.48
Investments	4.58	39	45	29	26	34	47	42	51	53
Other Assets	67	74	73	84	97	112	118	108	132	152
Total Assets	89	131	140	136	144	168	190	174	206	229

Standalone Cash Flows (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	5.05	11	13	-0.88	-3.86	0.93	6.08	13	-5.46	-1.22
Cash from Investing Activity	-2.73	-9.80	-13	3.23	-1.55	-0.07	-6.05	-2.61	1.40	-0.15
Cash from Financing Activity	-0.05	0.47	-2.62	-1.18	3.56	0.35	0.15	-6.43	0.01	2.71
Net Cash Flow	2.28	1.45	-2.36	1.17	-1.86	1.21	0.18	3.62	-4.06	1.33

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Promoters	71.51%	71.51%	71.51%	71.51%	71.51%	71.51%	71.51%	71.51%	71.51%	71.51%	71.51%	71.51%
FIIs	0.14%	0.14%	0.14%	0.14%	0.14%	0.14%	0.23%	0.00%	0.00%	0.00%	0.00%	0.00%
DIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Public	28.35%	28.35%	28.35%	28.35%	28.35%	28.35%	28.26%	28.49%	28.49%	28.49%	28.49%	28.49%
Total Shareholders	4,110	4,046	4,040	3,981	4,005	4,098	3,831	3,949	4,054	4,105	4,213	4,286

Market Transactions

Date	Party	Category	Type	Avg Price (₹)	Total Value (₹)	Quantity	Percent Traded
May 24, 2024	Neelam mittal	Bulk	Sell	539.62	0.06 Cr	1,100	0.03
May 24, 2024	Neelam mittal	Bulk	Buy	537.82	1.17 Cr	21,709	0.60

Projection

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Sorry, no results found!

Documents

Presentations

Concalls

Reports

Presentations

No documents found!

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

AI Mode

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Standalone Quarterly Results (in ₹ Crores)

Total Figures

QoQ Changes

Total Figures

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	14	23	18	29	32	32	23	28	19	19
Expenses	12	17	16	23	21	26	17	25	17	14
Operating Profit	1.75	6.16	2.10	6.25	11	6.51	6.31	2.68	2.18	4.93
OPM %	12.92	26.61	11.62	21.63	33.92	20.20	27.45	9.53	11.58	25.91
Other Income	1.29	1.81	1.37	2.00	1.56	2.54	2.52	1.71	2.05	3.03
Interest	0.00	0.00	0.00	0.00	0.03	0.01	0.02	0.04	0.06	0.10
Depreciation	0.55	0.44	0.49	0.50	0.49	0.51	0.50	0.51	0.45	0.45
Profit Before Tax	2.49	7.52	2.98	7.74	12	8.53	8.31	3.85	3.72	7.42
Tax %	26.10	20.21	27.52	25.32	25.23	25.21	26.11	26.49	31.18	21.56
Net Profit	1.84	6.00	2.16	5.79	8.80	6.38	6.14	2.83	2.56	5.82
EPS in Rs	5.16	16.81	6.04	16.20	24.64	17.86	17.20	7.91	7.18	16.29

Standalone Profit Loss (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	95	92	91	71	97	76	78	84	115	102
Expenses	72	77	79	65	81	67	74	67	89	84
Operating Profit	23	15	12	5.29	16	8.21	3.81	16	26	18
OPM %	24.21	16.41	13.48	7.50	16.41	10.86	4.88	19.41	22.82	17.30
Other Income	3.04	4.47	5.16	5.89	3.79	5.77	6.93	6.47	8.34	8.82
Interest	0.03	0.03	0.02	0.06	0.04	0.14	0.34	0.00	0.10	0.13
Depreciation	1.56	1.56	1.90	2.01	1.98	1.99	2.18	1.98	2.01	1.97
Profit Before Tax	25	18	16	9.12	18	12	8.23	21	32	24
Tax %	33.66	31.05	34.11	21.79	23.04	23.70	21.65	23.84	25.61	26.63
Net Profit	16	12	10	7.13	14	9.05	6.45	16	24	18
EPS in Rs	45.61	34.84	28.61	19.96	37.95	25.32	18.04	44.21	67.61	48.58
Dividend Payout %	10.96	5.74	6.99	0.00	0.00	0.00	0.00	0.00	0.00	—

Standalone Balance Sheet (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	3.57	3.57	3.57	3.57	3.57	3.57	3.57	3.57	3.57	3.57
Reserves	67	106	113	110	112	133	152	151	174	198
Borrowings	0.37	2.17	1.74	1.44	5.91	6.25	6.04	0.00	0.00	3.56
Other Liabilities	19	20	22	21	23	25	28	20	28	25
Total Liabilities	89	131	140	136	144	168	190	174	206	229
Fixed Assets	18	18	22	22	22	20	23	24	23	22
CWIP	0.00	0.23	0.00	0.00	0.00	0.50	1.72	0.00	0.00	2.48
Investments	4.58	39	45	29	26	34	47	42	51	53
Other Assets	67	74	73	84	97	112	118	108	132	152
Total Assets	89	131	140	136	144	168	190	174	206	229

Standalone Cash Flows (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	5.05	11	13	-0.88	-3.86	0.93	6.08	13	-5.46	-1.22
Cash from Investing Activity	-2.73	-9.80	-13	3.23	-1.55	-0.07	-6.05	-2.61	1.40	-0.15
Cash from Financing Activity	-0.05	0.47	-2.62	-1.18	3.56	0.35	0.15	-6.43	0.01	2.71
Net Cash Flow	2.28	1.45	-2.36	1.17	-1.86	1.21	0.18	3.62	-4.06	1.33

Oscillators

BearishNeutralBullish

Neutral

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Moving Averages

BearishNeutralBullish

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
BDH	414.75	228 Cr	23.35	3.28	1.14	13.80	18.80	10.96
PHARMAID	49.98	176 Cr	—	3.40	0.00	-31.40	-26.23	-15.87
CORALAB	452.00	163 Cr	9.24	0.77	0.00	8.14	10.97	7.45
PARNAXLAB	127.20	143 Cr	12.93	1.58	0.00	12.26	12.71	5.29
QUESTLAB	86.30	142 Cr	10.02	1.58	0.00	15.73	15.08	10.18
APPL	161.00	110 Cr	—	5.49	0.00	15.67	18.38	8.59
MERCURYLAB	836.80	100 Cr	20.40	1.80	0.42	8.81	11.49	6.63

Overview

Detailed Summary

Coral Laboratories Limited (CLL) is a pharmaceutical company focused on manufacturing generic branded, nutraceuticals, OTC, and herbal medicines across India.

The company operates three production facilities located in Daman and Dehradun, enhancing its manufacturing capacity and scope.

Originally promoted by Navin B Doshi of the DWD group, Coral Labs raised Rs. 2.5 crores through a public issue to expand its manufacturing capabilities.

Coral Laboratories began commercial production at its ultra-modern unit in Daman in March 2004 and its plant in Dehradun in September 2006.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Formulations

Market Cap

163 Cr

Volatility

Low Risk

P/E Ratio

9.2

Industry P/E

43.8

PEG Ratio

0.2

P/B Ratio

0.8

52W High

859.00

52W Low

431.10

Sales CAGR

37.47%

15.00%

10.26%

10Y

4.32%

Profit CAGR

53.01%

38.74%

27.64%

10Y

7.69%

ROE

TTM

8.14%

8.70%

8.35%

10Y

9.43%

ROCE

TTM

10.97%

11.29%

10.74%

10Y

12.66%